233 related articles for article (PubMed ID: 29765249)
1. Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?
Forsythe A; Chandiwana D; Barth J; Thabane M; Baeck J; Shor A; Tremblay G
Cancer Manag Res; 2018; 10():1015-1025. PubMed ID: 29765249
[TBL] [Abstract][Full Text] [Related]
2. Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
Forsythe A; Chandiwana D; Barth J; Thabane M; Baeck J; Tremblay G
Breast Cancer (Dove Med Press); 2018; 10():69-78. PubMed ID: 29765247
[TBL] [Abstract][Full Text] [Related]
3. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR
Shao B; Li H; Zhang J; Liu X; Song G; Jiang H; Yan Y; Wang H; Wang J; Di L
Ann Transl Med; 2022 Aug; 10(16):901. PubMed ID: 36111005
[TBL] [Abstract][Full Text] [Related]
5. Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis.
Koleva-Kolarova RG; Oktora MP; Robijn AL; Greuter MJW; Reyners AKL; Buskens E; de Bock GH
Cancer Treat Rev; 2017 Apr; 55():16-25. PubMed ID: 28288388
[TBL] [Abstract][Full Text] [Related]
6. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
[TBL] [Abstract][Full Text] [Related]
7. Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.
Patterson-Lomba O; Dalal AA; Ayyagari R; Liu O; Dervishi E; Platt E; Chandiwana D; O'Shaughnessy JA
Breast J; 2019 Sep; 25(5):880-888. PubMed ID: 31290203
[TBL] [Abstract][Full Text] [Related]
8. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
9. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.
Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Wu EQ
Exp Hematol Oncol; 2015; 4():31. PubMed ID: 26693096
[TBL] [Abstract][Full Text] [Related]
11. Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients.
Chen IC; Hu FC; Lin CH; Huang SM; Chang DY; Cheng AL; Lu YS
Breast; 2021 Oct; 59():211-220. PubMed ID: 34298300
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial.
Yan H; Yu K; Zhang K; Liu L; Li Y
Oncotarget; 2017 Nov; 8(60):102458-102467. PubMed ID: 29254261
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
Kawalec P; Łopuch S; Mikrut A
Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
[TBL] [Abstract][Full Text] [Related]
15. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
Courtinard C; Gourgou S; Jacot W; Carton M; Guérin O; Vacher L; Bertaut A; Le Deley MC; Pérol D; Marino P; Levy C; Uwer L; Perrocheau G; Schiappa R; Bachelot F; Parent D; Breton M; Petit T; Filleron T; Loeb A; Pélissier SM; Robain M; Delaloge S; Bellera C
BMC Med; 2023 Mar; 21(1):87. PubMed ID: 36882736
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
19. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials.
Fillbrunn M; Signorovitch J; André F; Wang I; Lorenzo I; Ridolfi A; Park J; Dua A; Rugo HS
BMC Cancer; 2022 Sep; 22(1):1002. PubMed ID: 36131248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
